modelFinasteride
Extends from Pharmacolibrary.Drugs.ATC.D.D11AX10.
Information
| name: | Finasteride | |
| ATC code: | D11AX10 | route: | oral |
| compartments: | 1 | |
| dosage: | 5 | mg |
| volume of distribution: | 76 | L |
| clearance: | 9.1 | L/h |
| other parameters in model implementation | ||
Finasteride is a 5-alpha-reductase inhibitor used primarily to treat benign prostatic hyperplasia (BPH) and male pattern hair loss (androgenetic alopecia). It blocks the conversion of testosterone to dihydrotestosterone (DHT), a key factor in prostate enlargement and hair follicle miniaturization. Finasteride is an approved prescription medication, used today for these indications, mainly in adult males.
Pharmacokinetics
Pharmacokinetic parameters reported from healthy adult male volunteers after single oral dose administration.
References
Roth, MY, et al., & Amory, JK (2011). Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride. International journal of andrology 34(6 Pt 1) 541–547. DOI:10.1111/j.1365-2605.2010.01120.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/20969601
Yasumori, T, et al., & Taniguchi, T (2006). Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese. European journal of clinical pharmacology 62(11) 939–946. DOI:10.1007/s00228-006-0189-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16953457
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)